Empagliflozin reduces the risk of mortality and hospitalization for heart failure across Thrombolysis In Myocardial Infarction Risk Score for Heart Failure in Diabetes categories: Post hoc analysis of the EMPA-REG OUTCOME trial.
Subodh VermaAbhinav SharmaBernard ZinmanAnne Pernille OfstadDavid H FitchettMartina BrueckmannChristoph WannerIsabella ZwienerJyothis T GeorgeSilvio E InzucchiJaved ButlerC David MazerPublished in: Diabetes, obesity & metabolism (2020)
Applied to EMPA-REG OUTCOME, higher TRS-HFDM was associated with increased HHF and mortality risk. Empagliflozin reduced CV outcomes across TRS-HFDM categories. Higher ARRs were associated with higher risk scores.